

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 8-K

ENDO PHARMACEUTICALS HOLDINGS INC  
Form 8-K  
December 06, 2001

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): December 6, 2001  
(December 5, 2001)

ENDO PHARMACEUTICALS HOLDINGS INC.

-----  
(Exact name of registrant as specified in its charter)

DELAWARE	39040	13-4022871
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

100 Painters Drive Chadds Ford, Pennsylvania	19317
-----	-----
(Address of principal executive offices)	(Zip Code)

(610) 558-9800

-----  
(Registrant's telephone number, including area code)

N/A

-----  
(Former name or former address, if changed since last report)

Item 7. Financial Statements and Exhibits.

(a) Financial Statements of Business Acquired.

Not applicable.

(b) Pro Forma Financial Information.

Not applicable.

(c) Exhibits.

Exhibit Number	Description
----------------	-------------

## Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 8-K

- 99.1 Press release issued by Endo Pharmaceuticals Holdings Inc. on December 5, 2001
- 99.2 Certain pages from the Offer to Purchase on Schedule TO filed by Endo Pharmaceuticals Holdings Inc. on December 5, 2001 with the Securities and Exchange Commission

### Item 9. Regulation FD Disclosure.

On December 5, 2001, the Registrant commenced a self tender offer to purchase up to 13,500,000 of its outstanding Class A Transferable Warrants (Nasdaq: ENDPW) and any and all of its outstanding Class B Non-Transferable Warrants. The Registrant is offering to purchase the Warrants at a purchase price of \$0.75 per Warrant. The offer is scheduled to expire at 12:00 midnight, New York City time, on January 14, 2002, unless the Company elects to extend the offer. The offer is subject to various conditions described in the Offer to Purchase. In connection with the offer, the Registrant issued a press release, a copy of which is filed herewith as Exhibit 99.1 and is incorporated herein by reference. In addition, filed herewith as Exhibit 99.2, and incorporated herein by reference, are certain pages of the Offer to Purchase.

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ENDO PHARMACEUTICALS HOLDINGS INC.  
(Registrant)

By: /s/ CAROL A. AMMON

-----  
Name: Carol A. Ammon  
Title: President & Chief Executive  
Officer

Dated: December 6, 2001

### INDEX TO EXHIBITS

Exhibit No.	Description
99.1	Press release issued by Endo Pharmaceuticals Holdings Inc. on December 5, 2001
99.2	Certain pages from the Offer to Purchase on Schedule TO filed by Endo Pharmaceuticals Holdings Inc. on December 5, 2001 with the Securities and Exchange Commission

